![Soraya Madani](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Soraya Madani worked as the VP and Head of Portfolio Management & Regulatory Affairs at Viela Bio, Inc. from 2018 to 2020.
Anciens postes connus de Soraya Madani
Sociétés | Poste | Fin |
---|---|---|
VIELA BIO, INC. | Conseiller Juridique Général | 01/04/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Viela Bio, Inc.
![]() Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |